How to buy Haemonetics Corporation stock (HAE)

Haemonetics Corporation is a medical instruments & supplies business based in the US. Haemonetics Corporation shares (HAE) are listed on the NYSE and all prices are listed in US Dollars. Its last market close was $82.07 – a decrease of 1.52% over the previous week. Haemonetics Corporation employs 3,657 staff and has a trailing 12-month revenue of around $1.4 billion.

Our top picks for where to buy Haemonetics Corporation stock

Buy Haemonetics Corporation stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Haemonetics Corporation stock price (NYSE: HAE)

Use our graph to track the performance of HAE stocks over time.

Haemonetics Corporation shares at a glance

• Key figures

Information last updated 2024-12-11.

Latest market close	$82.07
52-week range	$70.25 - $97.97
50-day moving average more info button	$80.65
200-day moving average more info button	$82.68
Wall St. target price	$111.27
PE ratio more info button	34.5809
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$2.41

Is it a good time to buy Haemonetics Corporation stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Haemonetics Corporation price performance over time

Historical closes compared with the close of $82.25 from 2024-12-16

1 week (2024-12-11)	-1.31%
1 month (2024-11-18)	-6.71%
3 months (2024-09-18)	8.78%
6 months (2024-06-18)	-3.69%

1 year (2023-12-18)	-6.93%
2 years (2022-12-16)	5.00%
3 years (2021-12-17)	54.84%
5 years (2019-12-18)	119.34

Is Haemonetics Corporation stock undervalued or overvalued?

Valuing Haemonetics Corporation stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Haemonetics Corporation's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Haemonetics Corporation's P/E ratio

Haemonetics Corporation's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 35x. In other words, Haemonetics Corporation shares trade at around 35x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Haemonetics Corporation's PEG ratio

Haemonetics Corporation's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.3485. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Haemonetics Corporation's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.

Haemonetics Corporation's EBITDA

Haemonetics Corporation's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $314.2 million.

The EBITDA is a measure of a Haemonetics Corporation's overall financial performance and is widely used to measure a its profitability.

Haemonetics Corporation financials

Revenue TTM	$1.4 billion
Operating margin TTM	16.44%
Gross profit TTM	$530.8 million
Return on assets TTM	5.88%
Return on equity TTM	13.97%
Profit margin	9.1%
Book value	$17.44
Market Capitalization more info button	$4.2 billion

TTM: trailing 12 months

Haemonetics Corporation share dividends

We're not expecting Haemonetics Corporation to pay a dividend over the next 12 months.

Have Haemonetics Corporation's shares ever split?

Haemonetics Corporation's shares were split on a 2:1 basis on 2 December 2012 . So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your Haemonetics Corporation shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for Haemonetics Corporation shares which in turn could have impacted Haemonetics Corporation's share price.

Haemonetics Corporation share price volatility

Over the last 12 months, Haemonetics Corporation's shares have ranged in value from as little as $70.25 up to $97.97. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Haemonetics Corporation's is 0.321. This would suggest that Haemonetics Corporation's shares are less volatile than average (for this exchange).

Haemonetics Corporation overview

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app. It also provides automated blood component and manual whole blood collection systems, such as MCS brand apheresis equipment to collect specific blood components from the donor; disposable whole blood collection and component storage sets; SafeTrace Tx blood bank information system; and BloodTrack blood management software, a suite of blood management and bedside transfusion solutions that combines software with hardware components, as well as an extension of the hospital's blood bank information system. In addition, the company offers hospital products comprising TEG and HAS hemostasis analyzer systems that provide a comprehensive assessment of a patient's overall hemostasis; and TEG Manager software, which connects various TEG analyzers throughout the hospital, providing clinicians remote access to active and historical test results that inform treatment decisions. Further, it provides Cell Saver Elite +, an autologous blood recovery system for cardiovascular, orthopedic, trauma, transplant, vascular, obstetrical, and gynecological surgeries; and VASCADE products comprising VASCADE and VASCADE MVP, a technology platform which offers catheter-based delivery system and leverages the natural clot-inducing properties of collagen. The company sells its products through direct sales force, independent distributors, and sales representatives. Haemonetics Corporation was founded in 1971 and is headquartered in Boston, Massachusetts.

Frequently asked questions

null
What percentage of Haemonetics Corporation is owned by insiders or institutions?
Currently 0.892% of Haemonetics Corporation shares are held by insiders and 113.701% by institutions. How many people work for Haemonetics Corporation?
Latest data suggests 3,657 work at Haemonetics Corporation. When does the fiscal year end for Haemonetics Corporation?
Haemonetics Corporation's fiscal year ends in March. Where is Haemonetics Corporation based?
Haemonetics Corporation's address is: 125 Summer Street, Boston, MA, United States, 02110 What is Haemonetics Corporation's ISIN number?
Haemonetics Corporation's international securities identification number is: US4050241003 What is Haemonetics Corporation's CUSIP number?
Haemonetics Corporation's Committee on Uniform Securities Identification Procedures number is: 405024100